Arcturus: Janssen ends Hep B pact, Vietnam mfg deal terminated; ARCT-154 study extended

Arcturus Therapeutics Holdings Inc.

Janssen terminated Hep B collaboration; effective in 60 days; no penalties.
Mutual termination of Vietnam COVID-19 vaccine manufacturing deals with Vinbiocare; no penalties.
New Study Support Agreement for ARCT-154 vaccine study; payments to Vinbiocare through Q1 2025 plus royalty.
Arcturus takes on financial responsibility for continuing clinical activities in Vietnam.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. entered into Study Support Agreement with Vinbiocare Biotechnology Joint Stock Company valued at limited payments through Q1 2025; single digit percentage of net sales of ARCT-154 up to a capped am (effective 2022-10-31).

Action: entry
Counterparty: Vinbiocare Biotechnology Joint Stock Company
Value: limited payments through Q1 2025; single digit percentage of net sales of ARCT-154 up to a capped am
Effective: 2022-10-31

Exact text from the filing

On October 31, 2022, Arcturus Therapeutics, Inc. (“Arcturus”), a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc., entered into a Study Support Agreement (the “Support Agreement”) with Vinbiocare Biotechnology Joint Stock Company (“Vinbiocare”), a company established under the laws of Vietnam.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. terminated Research Collaboration and License Agreement with Janssen Pharmaceuticals, Inc. valued at terminated in its entirety for convenience; effective 60 days after notice; no penalties (effective 2022-10-31).

Action: termination
Agreement: collaboration
Counterparty: Janssen Pharmaceuticals, Inc.
Value: terminated in its entirety for convenience; effective 60 days after notice; no penalties
Effective: 2022-10-31

Exact text from the filing

On October 31, 2022, Arcturus received notice of termination from Janssen Pharmaceuticals, Inc. of the Research Collaboration and License Agreement, by and between Arcturus Therapeutics, Inc. and Janssen Pharmaceuticals, Inc., dated October 18, 2017 (the “Janssen Agreement”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. terminated Framework Drug Substance Supply Agreement with Vinbiocare Research and Manufacture Joint Stock Company valued at terminated by mutual agreement; no penalties (effective 2022-10-31).

Action: termination
Agreement: supply
Counterparty: Vinbiocare Research and Manufacture Joint Stock Company
Value: terminated by mutual agreement; no penalties
Effective: 2022-10-31

Exact text from the filing

and (2) Framework Drug Substance Supply Agreement (the “Supply Agreement”), signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc. and Vinbiocare Research and Manufacture Joint Stock Company, attached as Exhibit 10.33 to Arcturus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 10, 2021 (File No. 001-38942).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. terminated Technology License and Technical Support Agreement with Vinbiocare Research and Manufacture Joint Stock Company valued at terminated by mutual agreement; no penalties (effective 2022-10-31).

Action: termination
Agreement: license
Counterparty: Vinbiocare Research and Manufacture Joint Stock Company
Value: terminated by mutual agreement; no penalties
Effective: 2022-10-31

Exact text from the filing

On October 31, 2022, Arcturus and Vinbiocare executed a letter agreement terminating the following agreements, effective October 31, 2022: (1) Technology License and Technical Support Agreement (the “License Agreement”), signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc. and Vinbiocare Research and Manufacture Joint Stock Company, attached as Exhibit 10.32 to Arcturus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 10, 2021 (File No. 001-38942);

View on SEC.gov

Browse all material agreements →

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-22-001480

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.